The Role of IGF-I Receptor Bioactivity in Health and Disease
Joseph Janssen, M.D., PhD, Erasmus MC, Department of Internal Medicine, Rotterdam University
The main topic of research of Dr. Joseph A.M.J.L. Janssen is the Growth Hormone-Insulin-IGF-I axis in health, aging and disease.
Until now immunoassays are primarily used to estimate Growth hormone, IGF-I and insulin bioactivity. Kinase Receptor Activation (KIRA) bioassays are new alternatives to measure bioactivity of ligands in serum.
As one of the few laboratories in the world, Dr. Janssen has developed and running KIRA bioassays for the IGF-I receptor (IGF-IR), the insulin receptor-B (IR-B) and the insulin receptor-A (IR-A). This gives him the unique possibility to assess blood-borne mediated bioactivity of the IR-B, IR-A and IGF-IR in health, aging and disease.